Teva Pharmaceutical has announced a collaboration with Fosun Pharma to advance the global development of the ATTENUKINE ...

NextCure has entered a strategic partnership with Simcere Zaiming, to develop SIM0505, a new ADC targeting CDH6 for treating ...

Sweeping changes made by RFK Jr at the CDC have weakened the US's immunisation programme, according to former ACIP members.

MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, ...

After Biogen failed with a takeover bid in January, Supernus has swooped in to buy the postpartum depression pill developer.

Surovatamig shows promise, but needs to outperform established therapies such as Blincyto and Aucatzyl.

Ethris has entered a strategic partnership with Thermo Fisher Scientific for providing completely integrated mRNA solution.

NHS England now offers the "Trojan horse" therapy, belantamab mafodotin (Blenrep) for patients with multiple myeloma.

Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.

Lynozyfic’s global sales are projected to reach $707 million by 2031.

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

The future of US immunisation is up in the air as outspoken critics of vaccines populate an integral recommendation committee ...